BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a reminder to the market that the common share purchase warrants of the Company that were issued on November 1, 2019 (the “November Warrants”), have had their expiry date accelerated to January 21, 2021. The Company announces that as of today’s date, approx

North American Partners in Anesthesia is growing its New England regional service area with a new clinical partnership at Lawrence General Hospital.

Dr. Ari Berman and Dr. Philip Ozuah signed a new agreement between Yeshiva University and Montefiore Medicine launching a joint Yeshiva University -Albert Einstein College of Medicine B.A./B.S.-M.D. program for highly qualified high school graduates ensuring their path to an excellent medical education and an impactful career in hea

HemoSonics Welcomes FDA Support of Viscoelastic Coagulation Analyzers for COVID-19 Patients; Highlights the Benefits of the Quantra ® Hemostasis Analyzer

Ergotron, a global company focused on improving how people work, learn, play and care for others, announced the introduction of a Vaccination Cart to support safe and efficient COVID-19 vaccine distribution.

With more than 150,000 genetic tests available, at least 6.9 codes per claim and thousands of medical policies 1,2 , it’s virtually impossible for providers and payers to keep up with the complex and ever-changing world of genetic testing. Today, PreventionGenetics joins Concert Genetics’ Preferred Laboratory Network, which bring

Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing organization (“CDMO”). Following the sale to private equity firm NovaQuest Private Equity, Signet Healthcare Partners will retain a meaningful equity stake in CoreRx. The terms of the transaction are not disclosed. Based in Clearwater, FL, CoreRx is a leading provider of clinical and commercial CDMO services to a wide ra

SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Kathy L. Hibbs was nominated to the company’s Board of Directors and its Audit Committee

Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial.

Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced the appointment of Eileen Maus in Q4 2020 as the company’s president and CEO. Under her leadership, Renovia completed